文献速递糖尿病肥胖与代谢综合征

二甲双胍与生活方式干预对糖尿病预防计划及结局研究中死亡率的影响

Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.
PubMed 文献 · Diabetes Care · 2021-10-25

研究纳入3234名2型糖尿病高危成人,随机分配至强化生活方式干预、盲法二甲双胍或安慰剂,中位随访21年。癌症是主要死因(170例),其次为心血管疾病(131例)。与安慰剂相比,二甲双胍和生活方式干预均未降低全因、癌症或心血管疾病死亡率。

要点

  • 中位随访21年,二甲双胍未降低全因死亡率(HR 0.99,95%CI 0.79-1.25)。
  • 生活方式干预未降低全因死亡率(HR 1.02,95%CI 0.81-1.28)。
  • 癌症是2型糖尿病高危人群首位死因,其次为心血管疾病。

核心结论

  • 尽管二甲双胍和生活方式干预可预防糖尿病,但均未降低全因、癌症或心血管疾病死亡率。

研究设计与样本

  • 1996至1999年纳入3234名2型糖尿病高危成人,随机分配至强化生活方式干预、盲法二甲双胍或安慰剂。

主要发现

  • 中位随访21年(四分位距20-21),共453例死亡,癌症为首位死因(n=170),心血管疾病次之(n=131)。
  • 与安慰剂相比,二甲双胍对全因死亡(HR 0.99,95%CI 0.79-1.25)、癌症死亡(HR 1.04,95%CI 0.72-1.52)和心血管死亡(HR 1.08,95%CI 0.70-1.66)均无显著影响。
  • 生活方式干预对全因死亡(HR 1.02,95%CI 0.81-1.28)、癌症死亡(HR 1.07,95%CI 0.74-1.55)和心血管死亡(HR 1.18,95%CI 0.77-1.81)亦无显著影响。
  • 校正糖尿病状态与病程、BMI、累积血糖暴露及心血管风险后,全因死亡结果相似。

临床怎么用

  • 对于2型糖尿病高危人群,二甲双胍或生活方式干预用于预防糖尿病时,不应期望其降低长期死亡率。
  • 需重视该人群的癌症和心血管疾病筛查与管理,癌症是首位死因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether metformin or lifestyle modification can lower rates of all-cause and cause-specific mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. RESEARCH DESIGN AND METHODS: From 1996 to 1999, 3,234 adults at high risk for type 2 diabetes were randomized to an intensive lifestyle intervention, masked metformin, or placebo. Placebo and lifestyle interventions stopped in 2001, and a modified lifestyle program was offered to everyone, but unmasked study metformin continued in those originally randomized. Causes of deaths through 31 December 2018 were adjudicated by blinded reviews. All-cause and cause-specific mortality hazard ratios (HRs) were estimated from Cox proportional hazards regression models and Fine-Gray models, respectively. RESULTS: Over a median of 21 years (interquartile range 20-21), 453 participants died. Cancer was the leading cause of death (n = 170), followed by cardiovascular disease (n = 131). Compared with placebo, metformin did not influence mortality from all causes (HR 0.99 [95% CI 0.79, 1.25]), cancer (HR 1.04 [95% CI 0.72, 1.52]), or cardiovascular disease (HR 1.08 [95% CI 0.70, 1.66]). Similarly, lifestyle modification did not impact all-cause (HR 1.02 [95% CI 0.81, 1.28]), cancer (HR 1.07 [95% CI 0.74, 1.55]), or cardiovascular disease (HR 1.18 [95% CI 0.77, 1.81]) mortality. Analyses adjusted for diabetes status and duration, BMI, cumulative glycemic exposure, and cardiovascular risks yielded results similar to those for all-cause mortality. CONCLUSIONS: Cancer was the leading cause of mortality among adults at high risk for type 2 diabetes. Although metformin and lifestyle modification prevented diabetes, neither strategy reduced all-cause, cancer, or cardiovascular mortality rates.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lee CG, Heckman-Stoddard B, Dabelea D, et al. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021. PMID: 34697033. doi:10.2337/dc21-1046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。